Humira under the microscope: new registry tracks safety in chinese Crohn's patients
NCT ID NCT05394805
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry study followed 156 Chinese patients with moderate to severe Crohn's disease who were prescribed Humira (adalimumab) by their doctors. The goal was to see how safe and effective the drug is in real-world use over one year. Researchers tracked serious side effects and changes in disease activity. Since Humira is already approved for Crohn's, this study aims to confirm its benefits and risks in a Chinese population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Humira (adalimumab)
What this could lead to
If successful, this registry could confirm that Humira is safe and effective for treating Crohn's disease in Chinese patients, supporting its continued use.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. It only follows patients for one year, so long-term effects are not assessed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital of Southern Medical University /ID# 243386
Guangzhou, Guangdong, 510515, China
-
Nanjing Drum Tower Hospital /ID# 243385
Nanjing, Jiangsu, 210008, China
-
Peking University Third Hospital /ID# 242803
Beijing, Beijing Municipality, 100191, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 243213
Shanghai, Shanghai Municipality, 200065, China
-
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine /ID# 242801
Hangzhou, Zhejiang, 310018, China
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 242798
Guangzhou, Guangdong, 510120, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 242802
Hangzhou, Zhejiang, 310009, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 242799
Guangzhou, Guangdong, 510655, China
-
West China Hospital, Sichuan University /ID# 242804
Chengdu, Sichuan, 610041, China
-
Zhejiang Provincial Hospital of Chinese Medicine /ID# 243443
Hangzhou, Zhejiang, 310006, China